Cargando…

Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis

BACKGROUND: Tuberculosis (TB) is the leading cause of death from an infectious pathogen worldwide and the most prevalent opportunistic infection in people living with HIV. Isoniazid preventive therapy (IPT) reduces the incidence of active TB and reduces morbidity and mortality in HIV-infected patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerona, Roy, Wen, Anita, Chin, Aaron T., Koss, Catherine A., Bacchetti, Peter, Metcalfe, John, Gandhi, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871544/ https://www.ncbi.nlm.nih.gov/pubmed/27191185 http://dx.doi.org/10.1371/journal.pone.0155887

Ejemplares similares

Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
por: Metcalfe, John, et al.
Publicado: (2019)

Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis
por: Mave, Vidya, et al.
Publicado: (2017)

Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting
por: Metcalfe, John, et al.
Publicado: (2021)

Agreement Between Measures of Adherence to Isoniazid Preventive Therapy Among People With HIV in Uganda
por: Forman, Leah S, et al.
Publicado: (2022)

Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
por: Jenkins, Helen E., et al.
Publicado: (2011)

Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305
por: Rosen, Elias P., et al.
Publicado: (2023)

Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital
por: Chung, Sung Jun, et al.
Publicado: (2020)

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

1694 Risk factors and outcomes of isoniazid hepatotoxicity in children with latent tuberculosis
por: Devrim, Ilker, et al.
Publicado: (2014)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?
por: Ha, Lawrence, et al.
Publicado: (2017)

Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania
por: Shayo, Grace A., et al.
Publicado: (2015)

Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
por: Baxi, Sanjiv M., et al.
Publicado: (2015)

Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?
por: Navalkele, Bhagyashri, et al.
Publicado: (2020)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis
por: Oscanoa, Teodoro J., et al.
Publicado: (2023)

Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area
por: Moon, Hyung Hwan, et al.
Publicado: (2017)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

A Case of Acute Liver Failure in a Patient on Isoniazid Prophylaxis for Latent Tuberculosis
por: Philipose, Jobin, et al.
Publicado: (2022)

House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study
por: Chang, Alicia H, et al.
Publicado: (2013)

Antiretroviral Therapy Adherence During and Postbreastfeeding Cessation Measured by Tenofovir Levels in Hair
por: Nematadzira, Teacler G., et al.
Publicado: (2022)

Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa
por: Szakacs, Tom A, et al.
Publicado: (2006)

Lack of Adherence to Isoniazid Chemoprophylaxis in Children in Contact with Adults with Tuberculosis in Southern Ethiopia
por: Garie, Kefyalew T., et al.
Publicado: (2011)

Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study
por: Denholm, Justin T, et al.
Publicado: (2014)

1410. Isoniazid Therapy for Latent Tuberculosis Infection in Patients with Cancer Treated with Checkpoint Inhibitors Immunotherapy
por: Malek, Alexandre, et al.
Publicado: (2021)

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report
por: Li, Tsung-Lun, et al.
Publicado: (2021)

Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP)
por: Liu, Albert Y., et al.
Publicado: (2014)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study
por: Heyd, Amber, et al.
Publicado: (2021)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid
por: de Oyarzabal, Eleane, et al.
Publicado: (2019)

Isoniazid-Induced Severe Hepatotoxicity: An Infrequent but Preventable Cause of Liver Failure in Children Treated for Latent Tuberculosis Infection
por: Desrochers, Dan, et al.
Publicado: (2011)

Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors
por: Lai, Edward Chia-Cheng, et al.
Publicado: (2021)

Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review
por: Shahid, Noor ul ain, et al.
Publicado: (2022)

Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection
por: Wang, Tsai-Yu, et al.
Publicado: (2022)

Self-reported adherence and associated factors to isoniazid preventive therapy for latent tuberculosis among people living with HIV/AIDS at health centers in Gondar town, North West Ethiopia
por: Ayele, Asnakew Achaw, et al.
Publicado: (2017)

Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence
por: Gandhi, Monica, et al.
Publicado: (2018)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Evaluation of Biochip System in Determining Isoniazid and Rifampicin Resistances of Mycobacterium Tuberculosis in Sputum Samples
por: Lu, Wei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6e3uh8re0582qfutonnttsja4q